2022 BioInfect Conference
The global COVID-19 pandemic has highlighted the importance of infectious disease control and antimicrobial resistance is one of the biggest public health challenges of our time. With the WHO declaring AMR one of the top 10 global public health threats facing humanity and with 3.57 million deaths associated with resistant pathogens in 2019, it is imperative that we tackle this serious threat now.
Antimicrobial resistance today
Antimicrobial resistance arises when the organisms that cause infection evolve ways to survive treatment. Once standard treatments are ineffective, it is easier for infections to persist and spread. These resistant organisms can be found in people, animals, food and the environment. The rise and spread of antimicrobial resistance are creating a new generation of ‘superbugs’ that cannot be treated with existing medicines.
Drug-resistant bacteria infect over 50m people worldwide killing over 700,000 people each year. Without effective antibiotics, even minor surgery and routine operations could become high-risk procedures if serious infections can’t be treated.
Our Partnership Lead (Patient-focused Partnerships), Dr Beverley Isherwood will be taking part in the session ‘Patient Engagement’ discussing ‘Partnering for Impact: The CF AMR Syndicate’ at 13:50.
